InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
January 20, 2026
Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LP-284 for the treatment of soft tissue sarcomas, marking the third orphan designation for the program and the sixth overall across the company clinical pipeline. The designation expands LP-284 beyond hematologic malignancies into solid tumors and reflects its synthetic […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
January 12, 2026
Lantern Pharma (NASDAQ: LTRN) announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India, marking a strategic inflection point as the company moves to industrialize its AI-enabled drug discovery capabilities at global scale. The Bengaluru hub will serve as Lantern’s global scale-up center for its proprietary “RADR (R)” AI […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
December 3, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
November 13, 2025
Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which showed a 48% clinical benefit rate at or above the therapeutic dose threshold along with a favorable safety profile and strong biomarker correlations. […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
November 10, 2025
• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across oncology Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer drug developer, is using large-scale machine learning to discover new therapies, reposition existing molecules, and target high-unmet-need oncology indications. […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments
November 6, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR(R) platform, will host a webcast at 9 a.m. ET (6 a.m. PT) on Thursday, Nov. 13, 2025, to review third-quarter operating and financial results. President and CEO Panna Sharma and other members of the management team will discuss quarterly performance, […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present AI Drug Discovery Platforms at Inaugural AI4BM Symposium
October 30, 2025
Lantern Pharma (NASDAQ: LTRN) will present its commercially deployed AI research platforms, predictBBB.ai and LBx-AI, at the inaugural AI for Biology and Medicine symposium hosted by the University of North Texas. The company will showcase how machine learning is accelerating drug development and precision oncology, including 94.1% accuracy in predicting blood-brain barrier permeability and 86% […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress
October 28, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform oncology drug discovery and development, presented clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress in New York City, showing a confirmed complete metabolic response in a 41-year-old patient with […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30
October 24, 2025
Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery, announced that its management team will present at the ThinkEquity Conference on Thursday, Oct. 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York. To view the […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advancing Drug Discovery with PredictBBB.ai(TM) Partnership
October 22, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company, has partnered with Hoth Therapeutics (NASDAQ: HOTH) to deploy its AI-powered platform, PredictBBB.ai(TM), in streamlining drug development. The platform, boasting 94% accuracy, predicts whether drug candidates can cross the blood-brain barrier—a major challenge in developing treatments for neurological conditions. By integrating PredictBBB.ai(TM), Hoth aims to reduce development […]
InvestorNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment
October 14, 2025
Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a recent article that discussed its preparation for the launch of a trial targeting a rare pediatric disease, planned for […]
Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development
October 10, 2025
In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of dollars. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, aims to challenge that timeline. In a recent discussion titled “From Discovery to […]
Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development
October 1, 2025
Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process (https://ibn.fm/VIL67). The platform, called PredictBBB.ai(TM), is a next-gen AI tool that was designed to help determine whether a […]
FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy
September 30, 2025
Clinical-stage cancer technology company Lantern Pharma (NASDAQ: LTRN) is preparing for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026, in the wake of the company’s optimistic meeting with the U.S. Food and Drug Administration (“FDA”) to receive critical guidance on the company’s trial design and the FDA’s regulatory pathway. […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Aligns With Industry Call to Fix “Broken” Biotech Model
September 25, 2025
Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical-stage biopharmaceutical company leveraging its RADR AI platform to transform oncology drug development, was highlighted in a Dallas Innovates article covering the 2025 BioNTX iC3 Summit, where biotech leaders declared the traditional model “broken.” CEO Panna Sharma, serving as moderator and panelist, was quoted in the piece: “The process […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer
September 18, 2025
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. The company recently “completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (‘NSCLC’) patients,” reads a recent article. “Completing […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity
September 16, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints, showing a favorable safety and pharmacokinetic profile with early signs of antitumor activity. The open-label study in 63 patients with advanced relapsed or refractory solid tumors, including GBM, demonstrated […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast
September 10, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary RADR(R) AI platform, is featured in the latest episode of IBN’s BioMedWire Podcast. President, CEO and Director Panna Sharma discusses the company’s mission to accelerate cancer drug development using AI, outlines progress across three ongoing clinical trials and shares his […]
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)
September 10, 2025
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial
September 3, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven clinical-stage oncology company, announced the completion of a Type C meeting with the U.S. Food and Drug Administration, which provided guidance on the regulatory pathway and design of a planned pediatric trial targeting CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT). The FDA supported Lantern’s proposal for a parallel […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development
August 28, 2025
Lantern Pharma (NASDAQ: LTRN) recently unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). “The technology is integrated into the company’s RADR(R) platform, which supports AI-guided drug development,” reads a recent article. “By embedding this technology into RADR(R), Lantern […]
Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements
August 25, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, reported second-quarter 2025 results while outlining clinical progress, intellectual property gains, and new developments in its RADR(R) artificial intelligence platform. The company continues to advance multiple oncology drug candidates aimed at high-value markets, supported by a […]
Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool
August 19, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has introduced predictBBB.ai(TM), a publicly available AI module designed to predict blood-brain barrier (“BBB”) permeability for small-molecule drugs with unprecedented speed and accuracy (https://ibn.fm/9RZYo). Crossing the BBB remains one of the pharmaceutical industry’s most persistent challenges. […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform
August 14, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials — LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma — along with completion of LP-184 […]
Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
August 7, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (“NSCLC”) patients (https://ibn.fm/JXFqG). The company enrolled 10 patients across five […]
Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations
August 6, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). The technology is integrated into the company’s RADR(R) platform, which […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial
August 6, 2025
Lantern Pharma (NASDAQ: LTRN) announced that its wholly owned subsidiary, Starlight Therapeutics, has received FDA clearance for an Investigational New Drug (“IND”) application to initiate a Phase Ib/2a clinical trial of STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (“GBM”) at first progression. The study will evaluate safety, tolerability and preliminary efficacy […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy
August 4, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug development company, has launched predictBBB.ai(TM), a public AI module that predicts blood-brain barrier (BBB) permeability of small molecules with 94% accuracy, 95% sensitivity, and 89% specificity. Built on billions of molecular data points from Lantern’s proprietary data lake, the platform addresses the pharmaceutical challenge that only 2–6% […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan
July 31, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven developer of targeted cancer therapies using its proprietary RADR(R) platform, has completed targeted enrollment for its Phase 2 HARMONIC(TM) clinical trial in Japan ahead of schedule, enrolling 10 patients across five sites including the National Cancer Center Japan. The trial evaluates LP-300 with carboplatin and pemetrexed in never-smoker non-small […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
July 28, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and genomic data to accelerate oncology drug discovery, announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop, co-founder and former CEO of Oncoceutics Inc., brings over 20 years of experience in biotechnology leadership and financial markets, with a […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
July 23, 2025
Lantern Pharma (NASDAQ: LTRN) announced a complete metabolic response in a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell DLBCL during its ongoing Phase 1 trial of LP-284—the first such response observed with the candidate. The patient had failed three prior regimens, including CAR-T and bispecific antibody therapy, before responding after just two […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
July 21, 2025
Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin’s lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress
July 16, 2025
Lantern Pharma (NASDAQ: LTRN), a biotech company leveraging its RADR(R) AI platform to accelerate precision oncology drug development, has engaged IBN to lead its corporate communications strategy. With clinical programs targeting lung, brain, breast, and blood cancers—including three AI-guided candidates and a CNS-focused subsidiary—Lantern is advancing multiple FDA-designated therapies in active trials. The partnership with […]
IBN Initiates Coverage of Lantern Pharma Inc.
July 16, 2025
AUSTIN, Texas, July 16, 2025 (GLOBE NEWSWIRE) — via IBN — Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform to transform the cost, pace and precision of oncology drug development, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
July 15, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer […]
InvestorNewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
June 30, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. “Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins […]
Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial
June 26, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, recently reported an encouraging clinical outcome in its Phase 2 HARMONIC(TM) trial, where a patient with advanced non-small cell lung cancer (“NSCLC”) achieved a complete response using LP-300, a compound optimized through Lantern’s AI-powered platform, RADR(R) […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
June 16, 2025
Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieving a durable complete response following treatment with LP-300 in combination with standard chemotherapy. The patient, who had previously failed three lines of therapy including Keytruda(R), radiation, and Tagrisso(R), initially […]
Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
June 11, 2025
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT
May 30, 2025
Lantern Pharma (NASDAQ: LTRN) reported strong preclinical results for LP-184 in atypical teratoid rhabdoid tumors (“ATRT”), a rare and aggressive pediatric brain cancer. Presented by Dr. Eric Raabe of Johns Hopkins at the Society for Neuro-Oncology’s Pediatric Neuro-Oncology Conference, the data showed LP-184 significantly improved survival in two mouse models, with one model achieving a […]